- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal: Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer. (Pubmed Central) - Sep 5, 2024
The literature search was executed in PubMed and ClinicalTrials.gov to identify relevant articles and clinical trials published until December 2023. In the context of clinical trials, driven by the presence of specific molecular mutations or even in the absence of both conditions, systemic therapy TKIs are valuable weapons to be used in patients affected by aggressive forms of TC, waiting for further expansion of the treatment landscape with more efficacious and safer drugs.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Effects of three flavonoids on the metabolism of lenvatinib. (Pubmed Central) - Sep 4, 2024
Furthermore, the inhibitory type of luteolin on lenvatinib showed an un-competitive in RLM and a mixed in HLM. Collectively, flavonoids with liver protection, especially luteolin, may inhibit lenvatinib metabolism in vitro and in vivo.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Solanum torvum Induces Ferroptosis to Suppress Hepatocellular Carcinoma. (Pubmed Central) - Sep 3, 2024
ST displayed an additive effect with lenvatinib in Hep 3B cells and showed remarkable anti-HCC activity in lenvatinib-resistant Hep 3B cells. Collectively, the study shows that ST might have the potential to reduce lenvatinib use in clinical practice and salvage cases of lenvatinib resistance.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Metastases: Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma. (Pubmed Central) - Sep 2, 2024
As this report was based on a limited number of patients, more cases are required to investigate the efficacy of LP therapy in patients with UCS. No abstract available
- |||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Retrospective data, Review, Journal, Metastases: Efficacy and Safety of Sorafenib or Lenvatinib for Advanced Hepatocellular Carcinoma after Failure of First-Line Atezolizumab Plus Bevacizumab: A Systematic Review and Meta-Analysis. (Pubmed Central) - Aug 31, 2024
TACE-Len-T treatment significantly improved OS, PFS, ORR, and DCR over TACE-Len treatment, with a manageable safety profile in uHCC. Sorafenib or lenvatinib can provide effective treatment with manageable toxicity in patients with advanced HCC after disease progression under atezolizumab-bevacizumab.
- |||||||||| Inlyta (axitinib) / Pfizer
Journal: Therapeutic Senolysis of Axitinib-Induced Senescent Human Lung Cancer Cells. (Pubmed Central) - Aug 31, 2024
Axitinib-induced senescent lung adenocarcinoma A549 cells were drastically lysed by ABT-263. In A549-xenografted mice, combination therapy with axitinib and ABT-263 significantly suppressed tumor growth with the induction of apoptotic cancer cells.
- |||||||||| Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Review, Journal: Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials. (Pubmed Central) - Aug 26, 2024
This triple combination strategy may be an alternative treatment for infiltrative HCC management. By revealing their structure-activity relationships, pharmacological actions, and clinical trials, small-molecule drugs can offer broad prospects for the development of new medications.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date: Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma (clinicaltrials.gov) - Aug 26, 2024
P2, N=26, Recruiting,
By revealing their structure-activity relationships, pharmacological actions, and clinical trials, small-molecule drugs can offer broad prospects for the development of new medications. Trial completion date: Feb 2025 --> May 2026
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Biotinylated polyaminoacid-based nanoparticles for the targeted delivery of lenvatinib towards hepatocarcinoma. (Pubmed Central) - Aug 24, 2024
Furthermore, the enhanced in vivo efficacy of lenvatinib-loaded nanoparticles on nude mice HCC xenograft models was demonstrated by evaluating tumor burdens, apoptotic markers and histological scores after administration of lenvatinib-nanoparticles via intraperitoneal or oral route. Finally, in vivo biodistribution studies were performed, demonstrating the ability of the prepared drug delivery systems to significantly accumulate in the solid tumor by active targeting, due to the presence of biotin on the nanoparticle surface.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial primary completion date, HEOR, Real-world evidence: CA209-1275: Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients (clinicaltrials.gov) - Aug 23, 2024
P=N/A, N=327, Active, not recruiting,
In unresectable HCC patients, the incorporation of RFA to lenvatinib plus sintilimab demonstrated improved efficacy without compromising safety compared with lenvatinib plus sintilimab alone. Trial primary completion date: Apr 2024 --> Jun 2024 | Recruiting --> Active, not recruiting
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: MK-3475-A70: Pembrolizumab and Lenvatinib in Advanced Cervical Cancer (clinicaltrials.gov) - Aug 22, 2024
P2, N=35, Recruiting,
Trial primary completion date: Apr 2024 --> Jun 2024 | Recruiting --> Active, not recruiting Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- |||||||||| Enweida (envafolimab) / 3DMed, Ascletis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (clinicaltrials.gov) - Aug 22, 2024
P1/2, N=170, Recruiting,
Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal: The potential of lenvatinib in breast cancer therapy. (Pubmed Central) - Aug 22, 2024
Recent studies have explored the role of lenvatinib in breast cancer, including its various mechanisms of action and its use as a monotherapy or in combination to control breast cancer progression. This review will summarize the molecular mechanisms and research progress of lenvatinib in breast cancer treatment, discussing its potential applications and therapeutic prospects in managing breast cancer.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: LACTB suppresses liver cancer progression through regulation of ferroptosis. (Pubmed Central) - Aug 21, 2024
Importantly, LACTB is identified as a downstream target of lenvatinib, and adeno-associated virus-mediated overexpression and knockdown of LACTB notably enhance and attenuate the anti-tumour efficacy of lenvatinib in vivo, respectively. Taken together, our study reveals a novel action of LACTB and provides potential therapeutic strategies for enhancing the efficacy of lenvatinib in liver cancer.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Monotherapy, Metastases: Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (clinicaltrials.gov) - Aug 21, 2024
P2, N=400, Active, not recruiting,
Taken together, our study reveals a novel action of LACTB and provides potential therapeutic strategies for enhancing the efficacy of lenvatinib in liver cancer. Recruiting --> Active, not recruiting
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Sarcomatoid HCC: The Freak of TACE (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_5364;
The patient started Lenvatinib within 10 days of these findings...Figure: Figure 1: Staging MRI abdomen illustrating two well circumscribed T2 hyperintense, rim-enhancing lesions. The first is seen in segment 5/8 and measures 1.6 x 1.8cm and the second measures 1.2 x 1.5cm in segment 2.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Case Report: A Rare Form of Hepatocellular Carcinoma in a Patient With Inflammatory Bowel Disease (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_5219;
She was started on Lenvatinib to decrease risk of recurrence, and fortunately, she has remained in remission since...There are limited case reports of HCC in IBD patients, and all existing reports of FLC are in patients with UC. Herein we describe a case of FLC in a patient with newly diagnosed Crohn's disease.
- |||||||||| Kremezin (AST-120) / Mitsubishi Tanabe, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Now You See Me, Now You Don't: Spontaneous Remission of HCC (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1761;
Labs were notable for chronic HBV co-infection with Hepatitis D, HBV viral load of 60 IU/mL, ALT 91 U/L, AST 120 U/L, total bilirubin 1.4 mg/dL, AFP of 1429 ng/mL...He was referred to medical oncology, who recommended lenvatinib for treatment of unresectable HCC...During this interval, he was started on entecavir 0.5 mg daily for treatment of chronic HBV...MRI abdomen in 11/2017 demonstrated a 93 mm, ill-defined heterogenous mass involving the right lobe of the liver, predominantly in segment 5, 6 and 8 (A). By 12/2018, this mass was no longer recognized (B), and remained as such in 12/2019 (C) and on most recent imaging in 11/2023 (D).
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
An Unlikely Etiology of Colon Masses in a Patient With Three Known Primary Malignancies (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_869;
Case Description/ A 76-year-old man with a history of metastatic adenocarcinoma of the salivary glands (lung metastases, on maintenance pembrolizumab), RCC (diagnosed 5 years prior, treated with cryoablation, in remission), prostate adenocarcinoma (treated with radiation therapy, in remission), and hypertension presented with iron deficiency anemia felt to be out of proportion to his known active malignancy...The patient had progression of disease on lenvatinib and was transitioned to belzutifan...This highlights the importance of considering endoscopic evaluation in patients with iron deficiency anemia even if they have a known active non-GI malignancy. Figure: Descending colon mass
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Metastatic Renal Cell Carcinoma With Unusual Spread to the Pancreas, Biliary System, Ampulla of Vater, and Stomach (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_584;
Patient Update The patient's therapy was switched to lenvatinib and noted to have stable biliary disease with functioning stents as demonstrated by stable liver function tests (LFTs) and serial CT scans...Figure: A: MRI T1 Axial Imaging Demonstrating Pancreatic Head Mass (yellow arrow). B&C: Endoscopic Images Demonstrating Malignant Gastric Polyps.
- |||||||||| Synribo (omacetaxine mepesuccinate) / Teva, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A reverse docking approach to explore the anticancer potency of natural compounds by interfering metastasis and angiogenesis. (Pubmed Central) - Aug 17, 2024
Homoharringtonine and viniferin, both have higher binding affinities when compared to reference ligands, with docking scores of -180.96 and -180.36 against the protein MMP-9, respectively...In pharmacoinformatics investigations, the majority of our compounds were found to be non-toxic for the host. In this study, we suggested natural substances as cutting-edge anticancer treatments that target both angiogenesis and metastasis, which may aid in accelerating drug development and identifying viable therapeutic candidates.Communicated by Ramaswamy H. Sarma.
- |||||||||| Journal, HEOR, Combination therapy, Cost-effectiveness, Cost effectiveness: Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. (Pubmed Central) - Aug 16, 2024
In this study, we suggested natural substances as cutting-edge anticancer treatments that target both angiogenesis and metastasis, which may aid in accelerating drug development and identifying viable therapeutic candidates.Communicated by Ramaswamy H. Sarma. As one of the promising immuno-combination therapies in the first-line systemic treatment of HCC, camrelizumab plus rivoceranib demonstrated the potential to be the most cost-effective strategy, which warranted further studies to best inform the real-world clinical practices.
|
